PDS-01ADC is under clinical development by PDS Biotechnology and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase II drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PDS-01ADC’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PDS-01ADC overview
PDS01ADC (PDS0301, M9241 and NHSIL12) is under development for the treatment of small intestine cancer (small bowel cancer), metastatic castration sensitive and castration resistant prostate cancer (mCRPC), Kaposi sarcoma, metastatic transitional cell carcinoma (urothelial cell carcinoma), colorectal cancer, metastatic non-prostate genitourinary malignancies, metastatic clear cell renal cell cancer, HPV malignancies associated vulvar cancer, vaginal cancer, penile cancer, anal cancer, cervical cancer, oropharyngeal cancer, squamous cell rectal cancers, lung cancer, metastatic colorectal cancer, intrahepatic cholangiocarcinoma and esophageal cancer. It is administered through subcutaneous route. The drug candidate is an interleukin 12 (IL-12) fused antibody-drug conjugate (ADC) consisting of the human monoclonal IgG1 antibody NHS76 fused to two molecules of the human IL-12 heterodimer.
The drug candidate was also under development for the treatment of metastatic solid tumors including epithelial tumor, mesenchymal tumor, pancreatic adenocarcinoma, metastatic breast cancer, metastatic renal cell carcinoma and non-small cell lung cancer.
PDS Biotechnology overview
PDS Biotechnology is a biopharmaceutical company that develops vaccines and immunotherapies for cancer and infectious disease. It is investigating PDS0101 for the treatment of head and neck, HPV-positive anal, cervical, penile, vaginal, vulvar cancers and pre-metastatic HPV-associated oropharyngeal cancer (OPSCC); PDS-0201 to prevent tuberculosis; PDS0202 targeting influenza; and PDS0203 against COVID-19. The company is also evaluating PDS0102 for TARP-associated AML (acute myeloid leukemia), prostate and breast cancers; PDS0103 against MUC1-associated breast, colon, lung, ovarian and other cancers; and PDS0104 to treat melanoma. It utilizes Versamune and Infectimune, T-cell immune activating platform technologies. PDS Biotechnology is headquartered in Florham Park, New Jersey, the US.
For a complete picture of PDS-01ADC’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
